Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Nicholas Short, Nitin Jain, Farhad Ravandi, Tharakeswara K. Bathala, Aram Bidikian, Fadi Haddad, Patrice Nasnas, Naval Daver, Tapan M. Kadia, Rebecca Garris, Monica Kwari, Hagop Kantarjian, Elias Jabbour

Blood (2022) 140 (Supplement 1): 3182–3184.

https://doi.org/10.1182/blood-2022-170931

Published: 2022

Journal Articles

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Ana Ayala, Jon A Hernandez, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, William G. Wierda

Blood (2022) 140 (Supplement 1): 238–240.

https://doi.org/10.1182/blood-2022-170030

Published: 2022

Journal Articles

Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond

Oren Pasvolsky, Rima M. Saliba, Celina Ledesma, Uday R Popat, Amin M Alousi, Amanda L. Olson, Betul Oran, Chitra Hosing, Qaiser Bashir, Muzaffar H Qazilbash, Nicholas Short, Farhad Ravandi, Richard E Champlin, Elizabeth J Shpall, Partow Kebriaei

Blood (2022) 140 (Supplement 1): 7695–7696.

https://doi.org/10.1182/blood-2022-155916

Published: 2022

Journal Articles

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Robert E. Briski, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Koji Sasaki, Danielle Hammond, Nicholas Short, Farhad Ravandi, Yesid Alvarado, Sherry A. Pierce, Guillermo Garcia-Manero, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 4042–4044.

https://doi.org/10.1182/blood-2022-170029

Published: 2022

Journal Articles

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Fadi Haddad, Georgio Medawar, Rashmi Kanagal-Shamanna, Hector Alvarez, Sanam Loghavi, Naval Daver, Sherry A. Pierce, Elias Jabbour, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Hussein A Abbas, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 3196–3198.

https://doi.org/10.1182/blood-2022-169991

Published: 2022

Journal Articles

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Blood (2022) 140 (Supplement 1): 6206–6208.

https://doi.org/10.1182/blood-2022-165359

Published: 2022

Journal Articles

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

Jayastu Senapati, Nicholas Short, Abhishek Maiti, Hussein A Abbas, Naval Daver, Naveen Pemmaraju, Sherry A. Pierce, Kelly S. Chien, Koji Sasaki, Danielle Hammond, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 1427–1429.

https://doi.org/10.1182/blood-2022-169934

Published: 2022

Journal Articles

A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Daniel Nguyen, Elias Jabbour, Nicholas Short, Ghayas C. Issa, Musa Yilmaz, Naval Daver, Naveen Pemmaraju, Kelly S. Chien, Lucia Masarova, Farhad Ravandi, Nitin Jain, Wuliamatu Deen, Min Zhao, Christopher Loiselle, Lourdes Waller, Glenda Banks, Rebecca Garris, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 6127–6129.

https://doi.org/10.1182/blood-2022-167883

Published: 2022

Journal Articles

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Sai Prasad Desikan, Naval Daver, Sanam Loghavi, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Sherry A. Pierce, Keyur P. Patel, Hussein A Abbas, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 11788–11790.

https://doi.org/10.1182/blood-2022-166655

Published: 2022

Journal Articles

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Alex Bataller, Rashmi Kanagal-Shamanna, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Nicholas Short, Gautam Borthakur, Elias Jabbour, Danielle Hammond, Lucia Masarova, Irene Ganan-Gomez, Vera Adema, Hagop Kantarjian, Guillermo Garcia-Manero, Koji Sasaki

Blood (2022) 140 (Supplement 1): 9793–9795.

https://doi.org/10.1182/blood-2022-164962

Published: 2022

Journal Articles

Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements

Emmanuel Almanza Huante, Elias Jabbour, Marina Konopleva, Cesar Nunez, Sergej Konoplev, Nicholas Short, Naveen Pemmaraju, Fatima Zahra Jelloul, Guilin Tang, Hagop Kantarjian, Nitin Jain

Blood (2022) 140 (Supplement 1): 3178–3180.

https://doi.org/10.1182/blood-2022-169370

Published: 2022

Journal Articles

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Emmanuel Almanza Huante, Hagop Kantarjian, Kelly S. Chien, Courtney D. DiNardo, Nicholas Short, Abhishek Maiti, Guillermo Montalban-Bravo, Naval Daver, Jitesh D. Kawedia, Kayleigh Bowie, Sherry A. Pierce, Farhad Ravandi, Marina Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2022) 140 (Supplement 1): 3344–3346.

https://doi.org/10.1182/blood-2022-169670

Published: 2022

Journal Articles

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Blood (2022) 140 (Supplement 1): 3324–3326.

https://doi.org/10.1182/blood-2022-158566

Published: 2022

Journal Articles

Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial

Guillermo Garcia-Manero, Vera Adema, Samuel Urrutia, Feiyang Ma, Hui Yang, Irene Ganan-Gomez, Gautam Borthakur, Koichi Takahashi, Nicholas Short, Ghayas C. Issa, Kelly S. Chien, Guillermo Montalban-Bravo, Joby Joseph, Simona Colla

Blood (2022) 140 (Supplement 1): 2078–2080.

https://doi.org/10.1182/blood-2022-167703

Published: 2022

Journal Articles

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)

Jayastu Senapati, Farhad Ravandi, Courtney D. DiNardo, Ghayas C. Issa, Koji Sasaki, Marina Konopleva, Naveen Pemmaraju, Kelly S. Chien, Maro Ohanian, Elias Jabbour, Abhishek Maiti, Edith Roy, Ricardo Delumpa, Juan Rivera, Christopher Loiselle, Glenda Banks, Hagop Kantarjian, Nicholas Short

Blood (2022) 140 (Supplement 1): 3880–3882.

https://doi.org/10.1182/blood-2022-170773

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

Blood (2022) 140 (Supplement 1): 4872–4875.

https://doi.org/10.1182/blood-2022-162962

Published: 2022

Journal Articles

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies

Georgina Gener-Ricos, Koji Sasaki, Sanam Loghavi, Abhishek Maiti, Nicholas Short, Fadi Haddad, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Keyur P. Patel, Michael Andreeff, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 11830–11832.

https://doi.org/10.1182/blood-2022-167923

Published: 2022

Journal Articles

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 534–536.

https://doi.org/10.1182/blood-2022-164922

Published: 2022

Journal Articles

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 9078–9079.

https://doi.org/10.1182/blood-2022-167349

Published: 2022

Journal Articles

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2022) 140 (Supplement 1): 9050–9053.

https://doi.org/10.1182/blood-2022-171011

Published: 2022

NARROW

Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only